首页> 外文OA文献 >Mutational analysis of the binding pockets of the diketo acid inhibitor L-742,001 in the influenza virus PA endonuclease
【2h】

Mutational analysis of the binding pockets of the diketo acid inhibitor L-742,001 in the influenza virus PA endonuclease

机译:流行性感冒病毒PA核酸内切酶中二酮酸抑制剂L-742,001结合口袋的突变分析

摘要

The influenza virus PA endonuclease, which cleaves capped host pre-mRNAs to initiate synthesis of viral mRNA, is a prime target for antiviral therapy. The diketo acid compound L-742,001 was previously identified as a potent inhibitor of the influenza virus endonuclease reaction, but information on its precise binding mode to PA or potential resistance profile is limited. Computer-assisted docking of L-742,001 into the crystal structure of inhibitor-free N-terminal PA (PA-Nter) indicated a binding orientation distinct from that seen in a recent crystallographic study with L-742,001-bound PA-Nter (R. M. DuBois et al., PLoS Pathog. 8:e1002830, 2012). A comprehensive mutational analysis was performed to determine which amino acid changes within the catalytic center of PA or its surrounding hydrophobic pockets alter the antiviral sensitivity to L-742,001 in cell culture. Marked (up to 20-fold) resistance to L-742,001 was observed for the H41A, I120T, and G81F/V/T mutant forms of PA. Two- to 3-fold resistance was seen for the T20A, L42T, and V122T mutants, and the R124Q and Y130A mutants were 3-fold more sensitive to L-742,001. Several mutations situated at noncatalytic sites in PA had no or only marginal impact on the enzymatic functionality of viral ribonucleoprotein complexes reconstituted in cell culture, consistent with the less conserved nature of these PA residues. Our data provide relevant insights into the binding mode of L-742,001 in the PA endonuclease active site. In addition, we predict some potential resistance sites that should be taken into account during optimization of PA endonuclease inhibitors toward tight binding in any of the hydrophobic pockets surrounding the catalytic center of the enzyme.
机译:流感病毒PA核酸内切酶可裂解带帽的宿主前mRNA,从而启动病毒mRNA的合成,是抗病毒治疗的主要靶标。先前已将二酮酸化合物L-742,001确定为流感病毒核酸内切酶反应的有效抑制剂,但有关其与PA的精确结合模式或潜在耐药性的信息有限。 L-742,001在无抑制剂的N末端PA(PA-Nter)的晶体结构中的计算机辅助对接表明其结合方向不同于最近对L-742,001结合的PA-Nter(RM DuBois等人,PLoS Pathog.8:e1002830,2012)。进行了全面的突变分析,以确定PA催化中心或其周围疏水口袋中的哪些氨基酸变化改变了细胞培养物中对L-742,001的抗病毒敏感性。对于PA的H41A,I120T和G81F / V / T突变形式,观察到对L-742,001的明显(高达20倍)抗性。 T20A,L42T和V122T突变株的抗药性是2到3倍,而R124Q和Y130A突变株对L-742,001的敏感性高3倍。位于PA的非催化位点的几个突变对在细胞培养物中重构的病毒核糖核蛋白复合物的酶功能没有影响或仅具有边际影响,这与这些PA残基的保守性较低相一致。我们的数据提供了有关PA核酸内切酶活性位点中L-742,001结合模式的相关见解。此外,我们预测在优化PA内切核酸酶抑制剂时,在围绕酶催化中心的任何疏水口袋中紧密结合时,应考虑一些潜在的抗性位点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号